SCHEMBL17510289

SCHEMBL17510289

CC1CN(C(=O)OC(C)(C)C)CC1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.50
▸ USP30 Q70CQ3 2/20 0.47
▸ HPGD P15428 1/20 0.45
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RECQL P46063 1/20 0.43
▸ RORC P51449 1/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PREP P48147 1/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12142188 1.00 NR1H2 (0.50) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL16224550 1.00 NR1H2 (0.50) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL16727831 1.00 NR1H2 (0.50) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL16080222 1.00 NR1H2 (0.50) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL31363276 0.86 NR1H2 (0.45) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL13801217 0.86 NR1H2 (0.58) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL15764146 0.86 NR1H2 (0.58) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL12035619 0.86 NR1H2 (0.58) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL15764147 0.86 NR1H2 (0.58) NR1H2USP30HPGDUSP2SMN1; SMN2
SCHEMBL17438450 0.85 NR1H2 (0.50) NR1H2USP30HPGDUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655296-A1 CBL-B INHIBITORS Aurigene Oncology Limited (IN) 2025-12-03 — — EP disclosed
WO-2024220747-A2 FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF Lysoway Therapeutics, Inc. (US) 2024-10-24 — — WO disclosed
WO-2024156938-A1 CBL-B INHIBITORS ORION CORPORATION (FI) 2024-08-02 — — WO disclosed
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 — — EP disclosed
US-11129832-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2021-09-28 — — US disclosed
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-18 — — US disclosed
US-10010549-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2018-07-03 — — US disclosed
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-05-17 — — US disclosed
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010549-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 NR1H2 141/4885USP30 4599/4885HPGD 505/4885
US-11129832-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 NR1H2 141/4885USP30 4599/4885HPGD 505/4885
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NR1H2 141/4885USP30 4599/4885HPGD 505/4885
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NR1H2 141/4885USP30 4599/4885HPGD 505/4885
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NR1H2 141/4885USP30 4599/4885HPGD 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback